Jim Young, Heiner Bucher
Status: completed Duration: Apr 2015 - Sep 2016
Daclatasvir (DCV) is a new, direct-acting antiviral agent for the treatment of chronic hepatitis C virus infection. It received marketing authorization from the European Medicines Agency in August 2014 under an accelerated-review process on the basis of single-arm, phase II trial results. Using European data from patients included in a \'Named Patient Program\' and from the early post-marketing authorization period, this study will describe patient characteristics and effectiveness of DCV-based regimens in Europe prescribed outside of clinical trials. This project is funded by Bristol-Myers Squibb.